GuruFocus Updates (Free subscription) | 05/09/2008
Not long ago, Allen M. Demby, M.D., of Wyckoff, N.J., retired from practicing ophthalmology and became a registered investment adviser. So, I asked him, what financial mistakes has he seen many of his new clients making?
Medical,Health News and Articles (Free subscription) | 05/07/2008
May 2 — While diabetes has long been associated with the potentially sight-stealing disease diabetic retinopathy, it appears that another serious eye disease — glaucoma — may also be a complication of the metabolic disorder. A recent study in the journal Ophthalmology found that women with diabetes have about a 70 percent increased risk of [...]
Dr. Wes (Free subscription) | 05/05/2008
The growing pay gap of non-procedurally-based subspecialties is threatening acute shortages of physicians in those fields: A discipline built on spending time with patients to gather clues for a diagnosis, neuro-ophthalmology could become another casualty of a medical payment system that favors high-tech procedures over low-tech exams. The median income of a neuro-ophthalmologist at a teaching...
Medical News Today (Free subscription) | 05/04/2008
Three studies in the May 2008 issue of Ophthalmology, the journal of the American Academy of Ophthalmology, shed new light on important eye health issues: the role of antioxidant supplements, the relationship of visual acuity and mortality, and the complex causes of glaucoma.
Red Orbit (Free subscription) | 05/01/2008
JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc.
Business Wire (Free subscription) | 05/01/2008
SAN FRANCISCO--(BUSINESS WIRE)--Three studies in the May 2008 issue of Ophthalmology, the journal of the American Academy of Ophthalmology, shed new light on important eye health
Eurekalert (Free subscription) | 05/01/2008
Research highlights from the May 2008 issue of Ophthalmology include: New findings on vitamin E and cataracts in women; Good vision and longer life; and a Possible cause of glaucoma.
The Earth Times Online Newspaper (Free subscription) | 04/29/2008
BETHESDA, Md. - REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that Dr. Gabriel Sosne, Assistant Professor of Ophthalmology at Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, MI,
Medical News Today (Free subscription) | 04/29/2008
Soft contact lens wear does not accelerate the development of nearsightedness in children, a new study shows. Findings from the three year study, the largest randomized trial of its kind, were presented at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO).
Medical News Today (Free subscription) | 04/28/2008
Physicians representing the American Academy of Ophthalmology (Academy) and the International Society of Refractive Surgery (ISRS) spoke to a meeting of the FDA's Ophthalmic Devices Panel about the long track record of safety and effectiveness for LASIK eye surgery.
The Earth Times Online Newspaper (Free subscription) | 04/27/2008
... oral poster presentation at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Dr. Grant reported patients who received Xibrom in addition to Lucentis (the Combination Group) required 1.6 +/- 0.69 injections of Lucentis during the six-month study period, while patients who received Lucentis only received 4.5 +/- 0.41 injections (p=0.0002). The original...
The Earth Times Online Newspaper (Free subscription) | 04/25/2008
DURHAM, N.C. - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in four poster presentations at the 2008 Association for Research in Vision and Ophthalmology (ARVO) annual meeting April 27 - May 1, 2008 in Ft.
Business Wire (Free subscription) | 04/25/2008
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in four poster presentations at
Red Orbit (Free subscription) | 04/25/2008
ESBATech, a developer of antibody fragment therapeutics, has initiated a Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology.
Medical News Today (Free subscription) | 04/25/2008
ESBATech AG, a leading developer of antibody fragment therapeutics, announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers.
Click here to see all comments
MAXIDEX WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by Alcon Labs. Two days later I was BLIND Use Google and enter EPOCRATES...
anonymous - 05/09/2008